Arnold Bullock, MD
When Arnold Bullock, MD, completed his Washington University urology residency and joined the faculty in 1993, the medical school was leading a groundbreaking study on the benefits of PSA in prostate cancer screening. At the time, study participation among African American men (AAM) was only 4 percent.
Through community outreach, Bullock and partners at Siteman Cancer Center and the American Cancer Society increased that rate to 14 percent. With screening, the rate of advanced disease among AAM has dropped from 55 percent to under 10 percent.
Prompted by a recommendation from the U.S. Preventive Services Task Force against PSA-based screening, Bullock, radiation oncologist Lannis Hall, MD, MPH, and the Prostate Cancer Coalition are working harder than ever to inform the community of the continued risks of prostate cancer.
Gerald Andriole, MD, chief of urology, and Timothy Eberlein, MD, department chair and director of Siteman, have been key mentors and supporters. Siteman is supporting a new outreach effort through a marketing campaign.